A combination of high clusterin and low Aβ42 in cerebrospinal fluid associates with early Alzheimer’s neurodegeneration, hinting at a mechanistic interaction between the proteins.
Detecting oligomers in the cerebrospinal fluid is no easy feat. The latest test is among the most sensitive yet, but is it useful?
The first longitudinal data from DIAN conflict with some cross-sectional findings, revealing a small drop in CSF injury markers after the first appearance of symptoms of disease.
Low levels of 10 phospholipids in blood plasma correlated with future cognitive decline in older adults, hinting at diagnostic potential.
The amyloid imaging agent florbetapir predicts cognitive decline much like its forerunner, PiB.
Researchers have found protein traces of brain damage in the blood of hockey players who sustained a concussion. Could biomarkers help decide when athletes return to their sport?
A new test claims to detect Aβ oligomers in cerebrospinal fluid by exploiting their tendency to seed aggregation.
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
Do blood components really leak across an inflamed blood-brain barrier early on in the development of Alzheimer’s disease? Some GWAS hits and budding neuro-imaging and fluid markers are helping researchers find out.
A small longitudinal study suggests that atrophy begins in the frontoparietal cortex, not the hippocampus, in early Alzheimer's.
European and U.S. agencies approve a third amyloid PET tracer, florbetaben.
Will an antibody signature make for a new Alzheimer’s diagnostic?
A candidate reference method for measuring Aβ42 in cerebrospinal fluid brings researchers closer to standardization.
Big-data project takes on Alzheimer's with a biomarker computational challenge.
Brain-training websites tout their games’ potential to boost cognition, but strong evidence and firm backing by the scientific community have yet to surface.